Research from the CWMH: Screening for Postpartum Depression, Treatment Engagement, Barriers to Care
Further systematic research on outcomes after postpartum screening is needed to ensure that screening translates into improved clinical outcomes.
Further systematic research on outcomes after postpartum screening is needed to ensure that screening translates into improved clinical outcomes.
The FDA will review zuranolone for the treatment of depression in the first half of 2022.
This review discusses the novel neurosteroid antidepressant brexanolone for the treatment of postpartum depression.
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment. Â
Women may experience depression and post-traumatic symptoms, especially those who were separated from their newborns after delivery and those with severe COVID-19 illness during pregnancy or after delivery.Â
Postpartum depression (PPD) is a relatively common problem, affecting between 10% and 15% of women after delivery. Although it is difficult to reliably predict which women in the general population will experience postpartum depression, it [...]
In a given year, about 10% of mothers in the United States experience a major depressive episode (MDE). Roughly translated, this means about 1 in 10 children is exposed to maternal depression each year (Ertel [...]
In 2019, brexanolone was introduced by Sage Therapeutics as Zulresso, a novel treatment for postpartum depression. The oral version of this novel antidepressant – SAGE 217 or zuranolone – is now finishing up its Phase [...]
About 15% of women will experience postpartum depression after the birth of a child. While most of those women will have unipolar depression, a certain number of women will have bipolar depression. At this juncture, [...]
Post-traumatic stress disorder (PTSD) is common among women of child-bearing age. While we are increasingly attentive to screening for depressive symptoms during pregnancy and after delivery, less often do we inquire about PTSD symptoms. [...]